Nanogen (NGEN) Awarded New CDC Contract to Develop Molecular Diagnostic Test for Influenza and Avian Flu
Nanogen (Nasdaq: NGEN) announced it has been awarded a new $10.4 million, two-year contract from the U.S. Centers for Disease Control and Prevention (CDC) to develop a multi-analyte molecular diagnostic assay for Influenza. This new contract will have Nanogen develop a fast molecular test that simultaneously detects and differentiates Influenza Type A, Influenza Type B, seasonal flu (H1N1 and H3N2) strains, and Respiratory Syncytial Virus (RSV). The contract provides for a secondary, "reflex", test for avian flu strains (H5N1, H7N1, and H9N1) to be available for samples that are determined to be positive for Flu A but negative for seasonal flu. RSV is the most common cause of bronchiolitis and pneumonia among infants and children under one year of age.
You May Also Be Interested In
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
- Canaccord Genuity Reiterates a 'Buy' on InterMune Inc. (ITMN); Esbriet (pirfenidone) Positive GBA Assessment
- Medicis (MRX) Gets Verbal Notice of Allowance for ZYCLARA Patent on Actinic Keratosis
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
